June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Evaluation of the Hypertensive Phase after Ahmed Glaucoma Valve Implantation in Neovascular Glaucoma
Author Affiliations & Notes
  • Sunidhi Ramesh
    Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
  • Wesam Shamseldin Shalaby
    Glaucoma, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Jonathan S. Myers
    Glaucoma, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • L. Jay katz
    Glaucoma, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Marlene R. Moster
    Glaucoma, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Reza Razeghinejad
    Glaucoma, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Aakriti Garg Shukla
    Glaucoma, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Sunidhi Ramesh, None; Wesam Shalaby, None; Jonathan S. Myers, Aerie (C), Aerie (F), Aerie (S), Allergan (C), Allergan (S), Allergan (F), Avisi (C), Diopsys (F), Glaukos (C), Glaukos (F), Haag Streit (S), Haag Streit (F), MicroOptx (C), Nicox (F), Olleyes (C), Olleyes (F), Santen (F); L. Jay katz, Aerie (I), Allergan, Inc (C), Allergan, Inc. (S), Bausch & Lomb, Inc (C), Bausch & Lomb, Inc. (S), Glaukos Corp. (S), Glaukos Corp. (I), Mati Therapeutics, Inc. (I), Olleyes, Inc. (I); Marlene R. Moster, Aerie (C), Aerie (S), Aerie (F), Alcon (C), Alcon (S), Allergan (C), Allergan (S), Allergan (F), Bausch and Lomb (C), Bausch and Lomb (S), Bausch and Lomb (F), Glaukos (C), Glaukos (F), Qura (C), Santen (F); Reza Razeghinejad, None; Aakriti Garg Shukla, Allergan, Inc. (F)
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 3425. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sunidhi Ramesh, Wesam Shamseldin Shalaby, Jonathan S. Myers, L. Jay katz, Marlene R. Moster, Reza Razeghinejad, Aakriti Garg Shukla; Evaluation of the Hypertensive Phase after Ahmed Glaucoma Valve Implantation in Neovascular Glaucoma. Invest. Ophthalmol. Vis. Sci. 2021;62(8):3425.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the short- and intermediate-term outcomes of the Ahmed glaucoma valve (AGV) in neovascular glaucoma (NVG), comparing eyes with and without a hypertensive phase (HP).

Methods : This was a single-center retrospective case series of consecutive NVG eyes that underwent AGV implantation with ≥ 6-month follow-up. HP was defined as intraocular pressure (IOP) >21mmHg at ≥ 2 visits within the first 3 months following surgery. Reported outcomes included failure at month 6 and at the most recent visit. Failure was defined as IOP >21mmHg, progression to no light perception (NLP) vision, or glaucoma reoperations (all with IOP-lowering medications). Other secondary outcomes included IOP and number of glaucoma medications.

Results : 76 eyes of 74 patients (37 without HP and 39 with HP) with follow-up duration of 28.9±25.7 months (P=0.602) were included. Patient demographics, visual acuity (VA), number of medications, NVG etiology, and perioperative retina treatment were similar in both groups. Baseline IOP was higher in the HP group (P=0.001). At month 6, 13 HP (33.3%) eyes vs. 3 non-HP (8.1%) eyes met the failure criteria (P=0.01). However, at the most recent visit, failure was higher in the HP group; the difference did not reach statistical significance (53.8% vs 35.1%; P=0.113). Kaplan-Meier analysis showed similar cumulative failure in both groups (P=0.180) (Figure 1). Reasons for failure were similar between groups (P=0.237): high IOP in 9 (26.5%) eyes, progression to NLP in 10 (29.4%) eyes, glaucoma reoperation in 14 (41.2%) eyes, and tube removal in 1 (2.9%) eye.

With the exception of post-operative day 1, IOP during the first 6 postoperative months was significantly higher in the HP group (P<0.05 for all). At the most recent visit, IOP was similar in both groups (P=0.211) (Figure 2A), but number of medications was higher in the HP group (P=0.023) (Figure 2B). Postoperative complications were similar and infrequent in both groups.

Conclusions : HP eyes had higher preoperative IOP and more commonly failed in the first 6 months following AGV implantation in NVG compared to non-HP eyes. This study did not detect a significant difference in surgical failure at the most recent visit between the two groups, but HP eyes required a significantly higher number of medications.

This is a 2021 ARVO Annual Meeting abstract.

 

Figure 1: Kaplan-Meier curve of cumulative survival

Figure 1: Kaplan-Meier curve of cumulative survival

 

Figure 2: (A) IOP changes over time and (B) Number of medications over time

Figure 2: (A) IOP changes over time and (B) Number of medications over time

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×